SINGAPORE INSTITUTE OF ADVANCED MEDICINE HOLDINGS LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.1 SGD | 0.00% |
|
0.00% | 0.00% |
Income Statement Evolution (Annual data)
| Fiscal Period: June | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net sales 1 | 12.92 | 13.81 | 16.23 |
| EBITDA 1 | -6.623 | -11.01 | -10.91 |
| EBIT 1 | -8.662 | -13.32 | -13.74 |
| Operating Margin | -67.06% | -96.43% | -84.63% |
| Earnings before Tax (EBT) 1 | -9.386 | -14.48 | -18.96 |
| Net income 1 | -9.349 | -12.43 | -18.07 |
| Net margin | -72.38% | -89.98% | -111.32% |
| EPS 2 | -0.0175 | -0.0193 | -0.0257 |
| Free Cash Flow | - | 3.475 | -19.28 |
| FCF margin | - | 25.17% | -118.78% |
| FCF Conversion (EBITDA) | - | - | - |
| FCF Conversion (Net income) | - | - | - |
| Dividend per Share | - | - | - |
| Announcement Date | 02/02/24 | 02/02/24 | 02/02/24 |
1SGD in Million2SGD
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2021 | 2022 | 2023 |
|---|---|---|---|
| Net Debt 1 | 81.7 | 71.2 | 69.5 |
| Net Cash position 1 | - | - | - |
| Leverage (Debt/EBITDA) | -12.34 x | -6.466 x | -6.371 x |
| Free Cash Flow | - | 3.48 | -19.3 |
| ROE (net income / shareholders' equity) | - | -25.6% | -38.3% |
| ROA (Net income/ Total Assets) | - | -4.8% | -5.14% |
| Assets 1 | - | 258.6 | 351.4 |
| Book Value Per Share 2 | 0.1100 | 0.0800 | 0.1300 |
| Cash Flow per Share 2 | 0.0200 | 0.0200 | 0.0300 |
| Capex 1 | 5.45 | 4.09 | 14.4 |
| Capex / Sales | 42.16% | 29.61% | 88.93% |
| Announcement Date | 02/02/24 | 02/02/24 | 02/02/24 |
1SGD in Million2SGD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
- Stock Market
- Equities
- 9G2 Stock
- Financials Singapore Institute of Advanced Medicine Holdings Ltd.
